الفهرس 
Effect of growth hormone therapy on children with idiopathic short stature
AbstractOnly 14 pages are availabe for public view
 |  | from | 144 |  |  |
| | | from | 144 | | |
Abstract
Idiopathic short stature (ISS) is a short stature of unknown cause. In 2003, the food and drug administration (FDA) approved the use of growth hormone (GH) for ISS. Several studies have evaluated the effect of GH in children with ISS, in whom improved growth velocities and height standard deviation score (SDS) have been reported. To determine impact of GH treatment on children with ISS in the endocrinology unit of Atfal Masr children{u2019}s hospital aiming to identify the predictors of growth response. In a retrospective prospective cohort study we assessed 26 short children with fulfilling the criteria for ISS before and during the first 2 years of GH treatment. They were 14 males (53.8%) and 12 females (46.2%) and had heights > 2 SDS below the corresponding mean height for age and sex. The height velocity in the 1st year of treatment with GH ranged from 3cm to 15 cm with a mean ±SD of 8.4±3.5 cm / year and SDS value ranged from 5.0 to 0.1 with a mean ± SD of 2.4±1.1, while during the second year height velocity ranged from 3.5cm to 11.5cm with a mean ± SD of 6.6±2.3 cm / year and SDS ranged from 2.9 to 1.2 with a mean ± SD of 1.3±1.0. There was a negative correlation between bone age delay and height at start of treatment SDS (r = - 0.443, p = 0.023) growth hormone dose at start of treatment was negatively correlated with the height at start of treatment in cm (r = - 0.453, p = 0.020) and negatively correlated with the bone age at start of treatment r = - 0.413, p = 0.036